Kyverna Therapeutics, Inc. (KYTX) Stock

Kyverna Therapeutics, Inc. (KYTX) is a Healthcare stock trading at $8.06 (as of 2026-06-18), with a market capitalization of $517.98M and a trailing P/E of -2.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases. Its lead program, KYV-101, is an autologous CD19 CAR T-cell therapy in Phase I or Phase II trials for conditions including lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis, while KYV-201 is an allogeneic CD19 CAR T-cell candidate in preclinical development.

Valuation — source: SEC EDGAR (first-party)
Price	$8.06
Market Cap	$517.98M
P/E Ratio	-2.5
EV / EBITDA	-2.8
Price / Book	2.51
Price / Sales	57.08
DCF Value (model)	$-41.24
DCF Upside vs Price	-611.7%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$9.09M
Net Margin	-1773.8%
Return on Equity	-80.0%
Current Ratio	8.15
Revenue Growth (YoY)	-40.8%
EPS Growth (YoY)	9.3%
FCF Growth (YoY)	32.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	1.85 (grey)

Valuation vs Sector & Industry
Stock P/E	-2.5
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-111.8%
vs Industry	-114.5%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	GordonMD Global Investments LP ($36.63M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Warner Biddle
Employees	112
Country	US
IPO Date	2024-02-09

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.